# SAFETY DATA SHEET



Seahorse XF Hu T Cell Activation Assay Kit

# SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

**Product name** : Seahorse XF Hu T Cell Activation Assay Kit

: **2**-deoxyglucose (2-DG) **CAS** number 154-17-6 ImmunoCult™ Human Not applicable.

CD3/CD28 T Cell

Activator

Part no. (chemical kit) : 103759-100, 103766-100

: 2-deoxyglucose (2-DG) 103761-000 Part no. ImmunoCult™ Human CD3/CD28 T Cell 103760-000

Activator

1.2 Relevant identified uses of the substance or mixture and uses advised against

**Identified uses** : For research use only.

> 2-deoxyglucose (2-DG) 2 x 246.24 mg ImmunoCult™ Human CD3/CD28 T Cell 1 x 2 ml

Activator

: Not for use in diagnostic procedures (RUO). Uses advised against

1.3 Details of the supplier of the safety data sheet

Agilent Technologies LDA UK Ltd. 5500 Lakeside Cheadle Royal Business Park,

Cheadle, Cheshire, SK8 3GR

**United Kinadom** 

Tel: +44 (0) 345 712 5292

e-mail address of person : pdl-msds author@agilent.com

responsible for this SDS

1.4 Emergency telephone number

**Emergency telephone** 

number (with hours of

operation)

: CHEMTREC®: +(44)-870-8200418

## **SECTION 2: Hazards identification**

2.1 Classification of the substance or mixture

**Product definition** : 2-deoxyglucose (2-DG) Mono-constituent substance

> ImmunoCult™ Human CD3/CD28 T Cell

Activator

Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

2-deoxyglucose (2-DG) The product is not classified as hazardous according to UK CLP

Regulation SI 2019/720 as amended.

The product is not classified as hazardous according to UK CLP ImmunoCult™ Human CD3/CD28 T Cell

Activator Regulation SI 2019/720 as amended.

Ingredients of unknown

toxicity

: ImmunoCult™ Human

Percentage of the mixture consisting of ingredient(s) of

CD3/CD28 T Cell Activator unknown acute dermal toxicity: 1 - 10%

Percentage of the mixture consisting of ingredient(s) of

unknown acute inhalation toxicity: 1 - 10%

Percentage of the mixture consisting of ingredient(s) of

unknown acute oral toxicity: 1 - 10%

: 27/10/2023 Date of issue/Date of revision Date of previous issue Version: 3.1 : 29/04/2024 1/15

### **SECTION 2: Hazards identification**

Ingredients of unknown ecotoxicity

mmunoCult™ Human

Contains 1.2% of components with unknown hazards to the

CD3/CD28 T Cell Activator aquatic environment

No signal word.

No signal word.

Not applicable.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

**Hazard statements** 

Signal word : 2-deoxyglucose (2-DG)

ImmunoCult™ Human

CD3/CD28 T Cell Activator

: 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Activator

No known significant effects or critical hazards. No known significant effects or critical hazards.

**Precautionary statements** 

**Prevention** 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Activator

Response : 2-deoxyglucose (2-DG)

ImmunoCult™ Human

CD3/CD28 T Cell

Activator

: **2**-deoxyglucose (2-DG) **Storage** 

ImmunoCult™ Human CD3/CD28 T Cell

Activator

**Disposal** 2-deoxyglucose (2-DG)

> ImmunoCult™ Human CD3/CD28 T Cell

Activator

Supplemental label

elements

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell

Activator

: 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Activator

Not applicable. Not applicable.

mixtures and articles **Special packaging requirements** 

Containers to be fitted with child-resistant

**Tactile warning of** 

**Annex XVII - Restrictions** 

on the manufacture,

and use of certain dangerous substances,

placing on the market

fastenings

danger

: 2-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell Activator

2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell

Activator

Not applicable. Not applicable.

Not applicable. Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, **Annex XIII** 

PBT	Р	В	Т	vPvB	vP	vB
2-deoxyglucose (2-DG)						
N/A	N/A	N/A	N/A	N/A	N/A	N/A

Date of issue/Date of revision Date of previous issue : 29/04/2024 : 27/10/2023 Version : 3.1 2/15

### **SECTION 2: Hazards identification**

mmunoCult™ Human CD3/CD28 T Cell

Activator

assessed to be a PBT or a vPvB.

Other hazards which do not result in

classification

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell

None known. None known.

Activator

## **SECTION 3: Composition/information on ingredients**

: 2-deoxyglucose (2-DG) 3.1 Substances

Mono-constituent substance

This mixture does not contain any substances that are

ImmunoCult™ Human CD3/CD28 Mixture

T Cell Activator

Product/ingredient name	Identifiers	%	Classification	Type
2-deoxyglucose (2-DG) 2-deoxy-D-glucose	EC: 205-823-0 CAS: 154-17-6	100	Not classified.	[1]
			See Section 16 for the full text of the H statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier, are classified and contribute to the classification of the substance and hence require reporting in this section.

**Type** 

**Inhalation** 

2-deoxyglucose (2-DG)

[1] Constituent

Occupational exposure limits, if available, are listed in Section 8.

### SECTION 4: First aid measures

	4.1	Descri	ption (	of first	aid	measures
--	-----	--------	---------	----------	-----	----------

: **2**-deoxyglucose (2-DG) **Eye contact** Immediately flush eyes with plenty of water, occasionally

lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs. Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove

ImmunoCult™ Human CD3/CD28 T Cell

: **2**-deoxyglucose (2-DG)

Activator

any contact lenses. Get medical attention if irritation occurs. Remove victim to fresh air and keep at rest in a position

comfortable for breathing. Get medical attention if symptoms

occur.

ImmunoCult™ Human CD3/CD28 T Cell

Activator

Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a

fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

**Skin contact** : 2-deoxyglucose (2-DG) Flush contaminated skin with plenty of water. Remove

contaminated clothing and shoes. Get medical attention if symptoms occur.

ImmunoCult™ Human

CD3/CD28 T Cell Activator

Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if

symptoms occur.

Ingestion : **2**-deoxyglucose (2-DG)

Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms

ImmunoCult™ Human CD3/CD28 T Cell

Activator

Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms

occur.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version: 3.1 3/15

Seahorse XF Hu T Cell Activation Assay Kit

### **SECTION 4: First aid measures**

**Protection of first-aiders** 

: **2**-deoxyglucose (2-DG)

No action shall be taken involving any personal risk or without

suitable training.

ImmunoCult™ Human CD3/CD28 T Cell

Activator

No action shall be taken involving any personal risk or without

suitable training.

### 4.2 Most important symptoms and effects, both acute and delayed

#### Over-exposure signs/symptoms

: 2-deoxyglucose (2-DG) **Eve contact** 

ImmunoCult™ Human

No specific data. No specific data.

No specific data.

CD3/CD28 T Cell

Activator

Inhalation : 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

No specific data.

Activator

**Skin contact** : **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

No specific data. No specific data.

Activator

: **2**-deoxyglucose (2-DG) Ingestion

ImmunoCult™ Human

No specific data. No specific data.

CD3/CD28 T Cell

Activator

### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician

: **2**-deoxyglucose (2-DG)

ImmunoCult™ Human

CD3/CD28 T Cell

Activator

Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need

to be kept under medical surveillance for 48 hours.

**Specific treatments** 

: 2-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell

Activator

No specific treatment. No specific treatment.

# **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

Suitable extinguishing

media

: 2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell

Use an extinguishing agent suitable for the surrounding fire. Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing** 

media

**2**-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell

Activator

Activator

Activator

None known. None known.

### 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : 2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell

No specific fire or explosion hazard.

In a fire or if heated, a pressure increase will occur and the

container may burst.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 4/15

## **SECTION 5: Firefighting measures**

Hazardous combustion products

: **2**-deoxyglucose (2-DG)

Decomposition products may include the following materials:

carbon dioxide carbon monoxide

ImmunoCult™ Human CD3/CD28 T Cell Activator Decomposition products may include the following materials:

carbon dioxide carbon monoxide nitrogen oxides phosphorus oxides

5.3 Advice for firefighters

Special protective actions for fire-fighters

: 2-deoxyglucose (2-DG)

ImmunoCult™ Human

Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters

: 2-deoxyglucose (2-DG)

CD3/CD28 T Cell

Activator

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full

face-piece operated in positive pressure mode.

ImmunoCult™ Human CD3/CD28 T Cell Activator Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: **2**-deoxyglucose (2-DG)

No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate

personal protective equipment.

ImmunoCult™ Human CD3/CD28 T Cell Activator No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate

personal protective equipment.

For emergency responders

: **2**-deoxyglucose (2-DG)

If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-

emergency personnel".

ImmunoCult™ Human CD3/CD28 T Cell

Activator

If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-

emergency personnel".

**6.2 Environmental precautions** 

: **2**-deoxyglucose (2-DG)

Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution

(sewers, waterways, soil or air).

ImmunoCult™ Human CD3/CD28 T Cell

Activator

Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution

(sewers, waterways, soil or air).

#### 6.3 Methods and material for containment and cleaning up

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 5/15

### SECTION 6: Accidental release measures

Methods for cleaning up : 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell Activator

Move containers from spill area. Vacuum or sweep up material and place in a designated, labelled waste container. Dispose of via a licensed waste disposal contractor. Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections

: See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

## **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

**Protective measures** 

: 2-deoxyglucose (2-DG)

Put on appropriate personal protective equipment (see Section 8).

ImmunoCult™ Human CD3/CD28 T Cell Activator

Put on appropriate personal protective equipment (see

Section 8).

Advice on general occupational hygiene : 2-deoxyglucose (2-DG)

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

ImmunoCult™ Human CD3/CD28 T Cell Activator

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking

and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8

for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

**Storage** 

: **2**-deoxyglucose (2-DG)

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and wellventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials

ImmunoCult™ Human CD3/CD28 T Cell Activator

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and wellventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials

before handling or use.

before handling or use.

### 7.3 Specific end use(s)

Date of issue/Date of revision Date of previous issue : 29/04/2024 : 27/10/2023 Version: 3.1 6/15

Seahorse XF Hu T Cell Activation Assay Kit

## **SECTION 7: Handling and storage**

Recommendations

2-deoxyglucose (2-DG) ImmunoCult™ Human

Industrial applications, Professional applications. Industrial applications, Professional applications.

CD3/CD28 T Cell

Activator

**Industrial sector specific** 

solutions

: 2-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell

Activator

Not available. Not available.

## **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### Occupational exposure limits

No exposure limit value known.

### **Biological exposure indices**

No exposure indices known.

Recommended monitoring procedures : Reference should be made to appropriate monitoring standards. Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

No DNELs/DMELs available.

#### **PNECs**

No PNECs available

#### 8.2 Exposure controls

Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### **Individual protection measures**

**Hygiene measures** 

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with sideshields.

## **Skin protection**

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection** 

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** 

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

**Environmental** exposure controls Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version: 3.1 7/15

## SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### 9.1 Information on basic physical and chemical properties

**Appearance** 

: 2-deoxyglucose (2-DG) **Physical state** Solid.

ImmunoCult™ Human

CD3/CD28 T Cell

Liquid. [Clear.]

Activator

Colour : **2**-deoxyglucose (2-DG)

ImmunoCult™ Human

Not available. White.

CD3/CD28 T Cell

Activator

: **2**-deoxyglucose (2-DG) **Odour** 

ImmunoCult™ Human CD3/CD28 T Cell

Not available. Not available.

Activator

**Odour threshold** : 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Not available. Not available.

Activator

Melting point/freezing

point

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human

146 to 147°C Not available.

CD3/CD28 T Cell

Activator

Initial boiling point and

boiling range

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human

Not available. Not available.

CD3/CD28 T Cell Activator

**Flammability** 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Not available. Not applicable.

Activator

Upper/lower flammability : 2-deoxyglucose (2-DG)

or explosive limits

ImmunoCult™ Human CD3/CD28 T Cell

Not applicable. Not available.

Activator

Flash point : 2-deoxyglucose (2-DG)

ImmunoCult™ Human

Not applicable. Not available.

CD3/CD28 T Cell

Activator

: 2-deoxyglucose (2-DG) Not applicable.

**Auto-ignition** temperature

pН

**Decomposition** temperature

: 2-deoxyglucose (2-DG) ImmunoCult™ Human

Not available. Not available.

CD3/CD28 T Cell

Activator

: 2-deoxyglucose (2-DG) ImmunoCult™ Human

Not available. Not available.

CD3/CD28 T Cell Activator

**Viscosity** : 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Not applicable. Not available.

Activator

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 8/15

## SECTION 9: Physical and chemical properties

Solubility(ies)

Media Result 2-deoxyglucose (2-DG) Soluble ImmunoCult™ Human CD3/CD28 T Cell Activator water Soluble

Partition coefficient: n-

octanol/water

**2**-deoxyglucose (2-DG) ImmunoCult™ Human

Not available. Not applicable.

CD3/CD28 T Cell Activator

Vapour pressure

	Vapour Pressure at 20°C			Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method
ImmunoCult™ Human CD3/CD28 T Cell Activator						
water	17.5	2.3	-	92.258	12.3	-

**Evaporation rate** 

: 2-deoxyglucose (2-DG) ImmunoCult™ Human

Not available. Not available.

CD3/CD28 T Cell

Activator

: **2**-deoxyglucose (2-DG) **Relative density** 

ImmunoCult™ Human CD3/CD28 T Cell

Not available. Not available.

Activator

2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell

Not applicable. Not available.

Activator

**Explosive properties** 

Vapour density

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human

Not available. Not available.

CD3/CD28 T Cell

Activator

: **2**-deoxyglucose (2-DG) **Oxidising properties** 

ImmunoCult™ Human CD3/CD28 T Cell

Not available. Not available.

Activator

**Particle characteristics** 

Median particle size

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell

Activator

Not available. Not applicable.

#### 9.2 Other information

No additional information.

# **SECTION 10: Stability and reactivity**

10.1 Reactivity

: 2-deoxyglucose (2-DG)

No specific test data related to reactivity available for this product or its ingredients.

ImmunoCult™ Human CD3/CD28 T Cell

Activator

No specific test data related to reactivity available for this

product or its ingredients.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version: 3.1 9/15

## SECTION 10: Stability and reactivity

10.2 Chemical stability

2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell

The product is stable. The product is stable.

10.3 Possibility of hazardous reactions : 2-deoxyglucose (2-DG)

Under normal conditions of storage and use, hazardous

reactions will not occur.

ImmunoCult™ Human

CD3/CD28 T Cell Activator

Under normal conditions of storage and use, hazardous

reactions will not occur.

10.4 Conditions to avoid

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell

Activator

Activator

Activator

No specific data. No specific data.

10.5 Incompatible

materials

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell Activator

May react or be incompatible with oxidising materials. May react or be incompatible with oxidising materials.

10.6 Hazardous decomposition products

: 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Under normal conditions of storage and use, hazardous decomposition products should not be produced. Under normal conditions of storage and use, hazardous

decomposition products should not be produced.

## **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

**Acute toxicity** 

**Acute toxicity estimates** 

N/A

Irritation/Corrosion

**Conclusion/Summary** : Not available.

**Sensitiser** 

**Conclusion/Summary** : Not available.

**Mutagenicity** 

**Conclusion/Summary** : Not available.

**Carcinogenicity** 

Conclusion/Summary : Not available.

**Reproductive toxicity** 

**Conclusion/Summary** : Not available.

**Teratogenicity** 

**Conclusion/Summary** : Not available. Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

**Aspiration hazard** 

Not available.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version: 3.1 10/15

## **SECTION 11: Toxicological information**

Information on likely routes of exposure

: 2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell

Not available. Not available.

Activator Potential acute health effects

Inhalation : 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

No known significant effects or critical hazards. No known significant effects or critical hazards.

Activator

: 2-deoxyglucose (2-DG) Ingestion

ImmunoCult™ Human

No known significant effects or critical hazards. No known significant effects or critical hazards.

CD3/CD28 T Cell Activator

: **2**-deoxyglucose (2-DG) Skin contact

ImmunoCult™ Human CD3/CD28 T Cell

No known significant effects or critical hazards. No known significant effects or critical hazards.

Activator

: 2-deoxyglucose (2-DG) Eye contact

ImmunoCult™ Human CD3/CD28 T Cell

No known significant effects or critical hazards. No known significant effects or critical hazards.

Activator

Symptoms related to the physical, chemical and toxicological characteristics

: **2**-deoxyglucose (2-DG) Inhalation

ImmunoCult™ Human

No specific data. No specific data.

CD3/CD28 T Cell

Activator

: **2**-deoxyglucose (2-DG) Ingestion

ImmunoCult™ Human CD3/CD28 T Cell

No specific data. No specific data.

Activator

: 2-deoxyglucose (2-DG) Skin contact

ImmunoCult™ Human CD3/CD28 T Cell

No specific data. No specific data.

Activator

: **2**-deoxyglucose (2-DG) **Eye contact** 

ImmunoCult™ Human

No specific data. No specific data.

CD3/CD28 T Cell

Activator

Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

**Potential immediate** 

effects

: Not available.

**Potential delayed** 

effects

: Not available.

**Long term exposure** 

Potential immediate

effects

: Not available.

**Potential delayed** 

effects

Not available.

Potential chronic health effects

**Conclusion/Summary** : Not available.

: 2-deoxyglucose (2-DG) General

ImmunoCult™ Human

CD3/CD28 T Cell

No known significant effects or critical hazards. No known significant effects or critical hazards.

Activator

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 11/15

Seahorse XF Hu T Cell Activation Assay Kit

## **SECTION 11: Toxicological information**

Carcinogenicity : 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell No known significant effects or critical hazards. No known significant effects or critical hazards.

Activator

Mutagenicity

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human No known significant effects or critical hazards. No known significant effects or critical hazards.

CD3/CD28 T Cell

Activator

**Reproductive toxicity** : **Z**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell No known significant effects or critical hazards. No known significant effects or critical hazards.

Activator

# **SECTION 12: Ecological information**

### 12.1 Toxicity

Conclusion/Summary : Not available.

### 12.2 Persistence and degradability

**Conclusion/Summary**: Not available.

### 12.3 Bioaccumulative potential

Not available.

### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

#### 12.5 Results of PBT and vPvB assessment

Product/ingredient name	PBT	Р	В	Т	vPvB	vP	vB
2-deoxyglucose (2-DG) 2-deoxy-D-glucose	N/A	N/A	N/A	N/A	N/A	N/A	N/A

**12.6 Other adverse effects** : No known significant effects or critical hazards.

# **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

### **Product**

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

**Hazardous waste** 

: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

### **Packaging**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

### **Special precautions**

: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 12/15

## **SECTION 14: Transport information**

	ADR/RID	IMDG	IATA
14.1 UN number	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-
14.3 Transport hazard class(es)	-	-	-
14.4 Packing group	-	-	-
14.5 Environmental hazards	No.	No.	No.

### **Additional information**

14.6 Special precautions for user

: **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not available.

## **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture UK (GB)/REACH

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

**Substances of very high concern** 

None of the components are listed.

Ozone depleting substances

Not listed.

**Prior Informed Consent (PIC)** 

Not listed.

**Persistent Organic Pollutants** 

Not listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

No listed substance

Label : Z-deoxyglucose (2-DG) ImmunoCult™ Human

CD3/CD28 T Cell Activator

Not applicable. Not applicable.

**Seveso Directive** 

This product is not controlled under the Seveso Directive.

**EU regulations** 

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 13/15

Seahorse XF Hu T Cell Activation Assay Kit

## SECTION 15: Regulatory information

: Not listed **Industrial emissions** 

(integrated pollution prevention and control) -

Air

: Not listed **Industrial emissions** 

(integrated pollution prevention and control) -

Water

15.2 Chemical safety

: This product contains substances for which Chemical Safety Assessments might still be required.

assessment

### International regulations

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

### **Montreal Protocol**

Not listed.

### **Stockholm Convention on Persistent Organic Pollutants**

Not listed.

### **Rotterdam Convention on Prior Informed Consent (PIC)**

Not listed.

### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

#### **Inventory list**

**United States** : Not determined.

### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

**Abbreviations and** 

: ATE = Acute Toxicity Estimate

acronyms

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/2008]

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent. Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification

Classification	Justification
Not classified.	

### Full text of abbreviated H statements

Not applicable.

### **Full text of classifications**

Not applicable.

Date of issue/ Date of

: 29/04/2024

revision

Date of previous issue : 27/10/2023

Version 3.1

**Notice to reader** 

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version: 3.1

Seahorse XF Hu T Cell Activation Assay Kit

## **SECTION 16: Other information**

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.

Date of issue/Date of revision : 29/04/2024 Date of previous issue : 27/10/2023 Version : 3.1 15/15